Omidenepag isopropyl

Clinical data
Trade names| Eybelis
Other names| DE-117
Identifiers

IUPAC name

* Propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate

CAS Number|

* 1187451-19-9

PubChem CID|

* 44230999

DrugBank|

* DB15071

UNII|

* G0G0H52U6K

KEGG|

* D10966

Chemical and physical data
Formula| C26H28N6O4S
Molar mass| 520.61 g·mol−1

Omidenepag isopropyl (INN; trade name Eybelis) is a pharmaceutical drug used for the treatment of glaucoma and ocular hypertension.

## Contents

* 1 Medical uses
* 2 Adverse effects
* 3 Pharmacology
* 4 History
* 5 References

## Medical uses

Omidenepag isopropyl as a 0.002% ophthalmic solution was approved in Japan in 2018 for the treatment of glaucoma and ocular hypertension.[1] It is being evaluated in the United States and Singapore for the same indications.[1]

## Adverse effects

The most common adverse effects of omidenepag isopropyl are conjunctival hyperemia and macular edema, including cystoid macular edema.[1]

## Pharmacology

Chemical structure of omidenepag, the active metabolite of omidenepag isopropyl

Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.[2] Omidenepag is a selective prostaglandin E2 receptor agonist.[3][4]

## History

Omidenepag isopropyl was developed by Ube Industries and Santen Pharmaceutical.[1]

## References

1. ↑ 1.0 1.1 1.2 1.3 "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs 78 (18): 1925–1929. December 2018. doi:10.1007/s40265-018-1016-1. PMID 30465134.
2. ↑ "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico. https://drugcentral.org/drugcard/5312.
3. ↑ "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science 59 (1): 145–153. January 2018. doi:10.1167/iovs.17-22745. PMID 29332128.
4. ↑ "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports 10 (1): 16018. September 2020. doi:10.1038/s41598-020-72538-x. PMID 32994409. Bibcode: 2020NatSR..1016018I.

0.00

(0 votes)

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Omidenepag_isopropyl&oldid=2877628"
*[CID]: Compound ID